Discover, Validate & Integrate More Specific CNS Biomarkers to Improve Early Detection, Enhance Precision Neuroscience & Reduce the Translational Bottleneck
As the only industry-driven forum focused exclusively on biomarker discovery and validation for neurodegenerative and neuroinflammatory diseases, the 3rd Fluid & Imaging Biomarkers in Neuroscience Summit unites biotech, pharma and academic scientists to transform diagnosis and monitoring of Alzheimer’s, Parkinson’s, ALS, and MS.
Join 50+ experts from Roche, Prothena, Eisai, Michael J. Fox Foundation and more to decode regulatory pathways, optimize IND timing, and harness breakthrough insights in p-tau217, alpha-synuclein, emerging omics platforms, and more.
As the field rapidly shifts toward blood-based diagnostics, high-sensitivity assays, and regulatory clarity, this is your unparalleled opportunity to collaborate with CNS biomarker leaders to shape a new wave of omics-based discoveries, surrogate endpoint success stories, pre-symptomatic detection technologies, and more.
"The diversity of topics and case studies stood out and very good coverage of both biofluids as well as imaging biomarkers"
Passage Bio
The Countdown is On: 3 Weeks to Go!
Industry News Round-Up: Why Biomarkers Are in the Spotlight
In just the past month, we’ve seen Roche achieve 91% plaque clearance with trontinemab and push its pTau217 blood test closer to routine adoption, Eisai expand real-world data for lecanemab while trialing new combination strategies, Eli Lilly secure EMA approval for donanemab, and the Michael J. Fox Foundation advance the first alpha-synuclein PET tracer into clinical testing. Each breakthrough underscores how rapidly fluid and imaging biomarkers are reshaping Alzheimer’s and Parkinson’s drug development, and why the conversations at this October’s 3rd Fluid & Imaging Biomarkers in Neuroscience Summit are so critical. With leaders from Roche, Eisai, Merck, Takeda, and the Michael J. Fox Foundation in the room, this is the one place to benchmark your strategy against the companies defining the future of biomarker-driven neurology.
- 50+ Translational, Precision Neuroscience, Bioanalytical, Biomarker & Data Scientists Sharing Ground-Breaking Research & Strategies
- 1 Separately Bookable Pre-Conference Workshop Day
- 8+ Hours of Networking with 80+ Likeminded Peers
World-Class Speaker Faculty Includes:
Fernanda Cerqueira
Senior Associate Director - Research Programs & Translational
Michael J. Fox Foundation
50+
Biomarker
Scientists
3rd
Year Running
8+
Networking Hours
18+
Speakers
Previously Attending Companies Include:
Official Partners
Explore Related Events
